Drug intelligence / Profile preview

DC-Vac

Development stage: Unknown
Lead developer: Dong-A University
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

DC-Vac is an autologous dendritic cell vaccine developed to treat non-small cell lung cancer (NSCLC). It is created by loading tumor lysate into a patient's own dendritic cells using electroporation and pulse technology. This process aims to enhance the dendritic cells' ability to present tumor-associated antigens, thereby inducing and proliferating antigen-specific T cells to generate an antitumor immune response.

Other names: autologous dendritic cell tumor vaccineautologous dendritic cell vaccine

Targets

CD80 (T-lymphocyte activation antigen CD80)CD40 (Cluster of differentiation 40 receptor)Neoantigen (Patient-specific tumor-associated neoantigen)

Beyond the preview

Go deeper on DC-Vac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DC-Vac.

Explore the full profile